IL17A and psoriasis: Eczematous dermatitis is induced by the treatment with tumor necrosis factor-alpha inbibitors in individuals with psoriasis.[11] Interestingly, an atopic history is a predicitive factor for TNFαinhibitor induced eczematous dermatitis.[11] Similarly, all psoriasis patients, developing eczematous dermatitis during the treatment with IL17 inhibitors showed an atopic history, and suggesting that the atopic history serves as a predictive factor for subsequent biologic treatment.[4] However, atopic history was not discernable in our case.